Krisztina Zsebo
Fondateur chez VST-Bio Corp.
Postes actifs de Krisztina Zsebo
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Biovest Consulting, LLC | President | 01/08/2015 | - |
| VST-Bio Corp. | Directeur/Membre du Conseil | 01/01/2022 | - |
| Fondateur | 01/01/2020 | - | |
| Directeur Général | 01/01/2020 | 01/01/2022 |
Historique de carrière de Krisztina Zsebo
Anciens postes connus de Krisztina Zsebo
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BIOCARDIA INC | Directeur/Membre du Conseil | 22/12/2020 | 18/10/2023 |
| Independent Dir/Board Member | 22/12/2020 | 18/10/2023 | |
VasoRx, Inc.
 VasoRx, Inc. Pharmaceuticals: MajorHealth Technology VasoRx, Inc. operates as a biotechnology company. It develops solutions for atherosclerotic plaque regression. The company was founded in 2018 and is headquartered in Santa Barbara, CA. | Directeur/Membre du Conseil | 01/04/2018 | 01/01/2022 |
| Directeur Général | 01/04/2018 | 01/01/2022 | |
| President | 01/04/2018 | 01/01/2022 | |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 21/05/2012 | 01/06/2015 |
| Directeur Général | 30/11/2009 | 01/06/2015 | |
| President | 01/01/2004 | 02/06/2014 | |
Enterprise Partners Venture Capital
 Enterprise Partners Venture Capital Investment ManagersFinance Enterprise Partners Venture Capital (Enterprise Partners) is a venture capital firm founded in 1985. The firm is headquartered in La Jolla, California. | Corporate Officer/Principal | - | 31/12/2008 |
| ALZA CORPORATION | Corporate Officer/Principal | 20/10/1998 | - |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | - | - |
Anaborex, Inc.
 Anaborex, Inc. Medical/Nursing ServicesHealth Services Anaborex, Inc. provides clinical research services for metabolic diseases. The company develops drugs for the treatment of cancer related wasting syndrome. It was founded in 2005 by Alan Saven and Jorge Nieva and is located in La Jolla, CA | Directeur/Membre du Conseil | - | - |
| ░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formation de Krisztina Zsebo
| University of Maryland | Undergraduate Degree |
| Oregon State University | Graduate Degree |
| University of California, Berkeley | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 18 |
Opérationnelle
| Director/Board Member | 6 |
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 4 |
Sectorielle
| Health Technology | 10 |
| Consumer Services | 4 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| CG ONCOLOGY, INC. | Health Technology |
| BIOCARDIA INC | Health Technology |
| Entreprise privées | 11 |
|---|---|
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Anaborex, Inc.
Anaborex, Inc. Medical/Nursing ServicesHealth Services Anaborex, Inc. provides clinical research services for metabolic diseases. The company develops drugs for the treatment of cancer related wasting syndrome. It was founded in 2005 by Alan Saven and Jorge Nieva and is located in La Jolla, CA | Health Services |
Enterprise Partners Venture Capital
Enterprise Partners Venture Capital Investment ManagersFinance Enterprise Partners Venture Capital (Enterprise Partners) is a venture capital firm founded in 1985. The firm is headquartered in La Jolla, California. | Finance |
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
Remedyne Corp.
 Remedyne Corp. Packaged SoftwareTechnology Services Remedyne Corp. develops software for asset management. | Technology Services |
Actavalon, Inc.
 Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | Health Technology |
VasoRx, Inc.
VasoRx, Inc. Pharmaceuticals: MajorHealth Technology VasoRx, Inc. operates as a biotechnology company. It develops solutions for atherosclerotic plaque regression. The company was founded in 2018 and is headquartered in Santa Barbara, CA. | Health Technology |
| Biovest Consulting, LLC | |
| VST-Bio Corp. |
- Bourse
- Insiders
- Krisztina Zsebo
- Expérience
